Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026220 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 166
- Enrollment target
NCT01026220 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 166 participants.
The verdict
NCT01026220, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 166 participants
- Enrollment target
Study Summary
This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells.
Interventions
- DRUG cyclophosphamide
- DRUG doxorubicin hydrochloride
- DRUG vinorelbine tartrate
- BIOLOGICAL bleomycin sulfate
- DRUG liposomal vincristine sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2009-12-07 |
| Est. Completion | 2022-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026220
The ClinicalTrials.gov registry entry for NCT01026220 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT01026220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026220 about?
NCT01026220 is a clinical study titled "Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma". This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by st...
What is the current status of trial NCT01026220?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 2009-12-07. Estimated completion is 2022-03-31.
What interventions are being tested in trial NCT01026220?
The interventions under investigation include: cyclophosphamide (DRUG), doxorubicin hydrochloride (DRUG), vinorelbine tartrate (DRUG), bleomycin sulfate (BIOLOGICAL), liposomal vincristine sulfate (DRUG).
Who is sponsoring clinical trial NCT01026220?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.